Business
MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC
MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC ...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"\n \n \n \n MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n MediPharm to design, manufacture and supply a liquid oral cannabis study drug for the Phase 2\n \n Life's end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study,\n \n to be conducted in the U.S., across 20 sites.\n \n \n The lead investigators have been awarded a total of\n \n US$16M\n \n grant from the US National Institutes of Health and the National Institute on Aging to support the research project.\n \n \n \n \n \n BARRIE, ON\n \n \n ,\n \n \n Aug. 9, 2022\n \n \n /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (\"MediPharm Labs\" or the \"Company\") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has entered into a research support agreement with the Keck School of Medicine of\n \n University of Southern California\n \n (\n \n USC\n \n ) to conduct a randomized double-blind placebo controlled Phase 2 trial on the efficacy of THC and CBD to treat hospice-eligible patients diagnosed with dementia and experiencing agitation.\n \n \n \n \n \n \n \n \n \n The lead investigators are\n \n Jacobo Mintzer\n \n , MD, MBA,\n \n Brigid Reynolds\n \n , ANP-BC, and the Alzheimer's Clinical Trial Consortium (ACTC).The ACTC is led by\n \n Paul Aisen\n \n , MD, Alzheimer's Therapeutic Research Institute at the\n \n USC\n \n ,\n \n Ron Petersen\n \n , MD, of Mayo Clinic, and\n \n Reisa Sperling\n \n , MD of the\n \n Brigham\n \n and Women's Hospital at\n \n Harvard Medical School\n \n . Consistent with MediPharm's commitment to clinical research and the progression and adoption of drugs containing cannabis, the Company will supply the Sponsor and the Principal Investigators with the study drug and placebo, and such other information and assistance as may be required during the course of the study.\n \n \n \n Management Commentary\n \n \n \n \n \n David Pidduck\n \n , CEO, MediPh...